# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Emily Bodnar reiterates Context Therapeutics (NASDAQ:CNTX) with a Buy and maintains $6 price...
Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of ...
HC Wainwright & Co. analyst Emily Bodnar reiterates Context Therapeutics (NASDAQ:CNTX) with a Buy and maintains $5 price...
CT-95, formerly owned by Link Immunotherapeutics, a mesothelin x CD3 T cell engaging bispecific antibody with first-in-class po...
- SEC Filing
Piper Sandler analyst Joseph Catanzaro initiates coverage on Context Therapeutics (NASDAQ:CNTX) with a Overweight rating and...
- SEC Filing
-SEC Filing
HC Wainwright & Co. analyst Emily Bodnar maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and raises the price ta...